Recombinant Proteins iso9001 ISO13485
搜索
 > 【LILRB2】重组蛋白信息

LILRB2信息

英文名称:Leukocyte immunoglobulin-like receptor subfamily B member 2
中文名称:白细胞免疫球蛋白样受体亚家族B成员2
靶点别称:Myeloid Inhibitory Receptor 10,CD85d Antigen,ILT4,LIR2,CD85d,LIR-2,Leukocyte immunoglobulin-like receptor 2,CD85 antigen-like family member D,Immunoglobulin-like transcript 4,ILT-4,Monocyte/macrophage immunoglobulin-like receptor 10,MIR-10,CD_antigen: CD8
上市药物数量:0
临床药物数量:1
最高研发阶段:临床二期

LILRB2产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
LI2-H5220
Human
Human LILRB2 / CD85d / ILT4 Protein, His Tag
CDD-H5259
Human
Human LILRB2 / CD85d / ILT4 Protein, Fc tag
LI2-H82F5
Human
Biotinylated Human LILRB2 / CD85d / ILT4 Protein, Fc,Avitag
 
评论(0)
 

LILRB2 分子别名

LILRB2,ILT4,LIR2,MIR10,CD85d

LILRB2 分子背景

Leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2) is also known as CD85 antigen-like family member D (CD85d), Immunoglobulin-like transcript 4 (ILT-4), Monocyte / macrophage immunoglobulin-like receptor 10 (MIR-10), which is a member of the the subfamily B class of LIR receptors. LILRB2 is receptor for class I MHC antigens. LILRB2 recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. LILRB2 competes with CD8A for binding to class I MHC antigens. LILRB2 / CD85d inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

LILRB2 参考文献

LILRB2临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
JTX-8064 JTX-8064 临床一期 Jounce Therapeutics 肿瘤 详情
MK-4830 MK-4830 临床二期 默沙东 肾细胞癌, 非小细胞肺癌 详情

消息提示

请输入您的联系方式,再点击提交!

确定